ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,199.50
-0.77%
US Tech 100
17,392.00
0.01%
다우존스 지수
38,763.45
-0.60%
Bitcoin
57,346.96
4.21%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) 뉴스

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:REGN
일자시간출처헤드라인심볼기업
2024/08/0805:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0805:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0805:05GlobeNewswire Inc.Regeneron Announces Investor Conference Presentations and Oncology Investor WebcastNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0705:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0605:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0605:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0605:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0605:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0223:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0205:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0205:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0120:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0120:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/08/0119:30GlobeNewswire Inc.Regeneron Reports Second Quarter 2024 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/07/3120:30GlobeNewswire Inc.Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative InnovationNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/07/1305:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/07/0820:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/07/0314:00GlobeNewswire Inc.Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/07/0301:53PR Newswire (US)Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/2820:00GlobeNewswire Inc.Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/2805:05GlobeNewswire Inc.Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/2706:30GlobeNewswire Inc.Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of MedicineNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1805:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1619:10GlobeNewswire Inc.Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1505:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1405:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1306:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1305:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1305:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
2024/06/1120:00GlobeNewswire Inc.Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)NASDAQ:REGNRegeneron Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:REGN

최근 히스토리

NYSE
KO
Coca Cola
FX
USDGBP
US Dollar vs Sterling
CCOM
US500
US 500
AMEX
XLF
Financial Select Sector
NYSE
AXP
American Express
NASDAQ
NVDA
NVIDIA
AMEX
XLV
Health Care Select Sector
CCOM
US100
US Tech 100
NYSE
VZ
Verizon Communications
NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
USOTC
RHHBY
Roche (QX)
USI
USTECH100
US Tech 100
NASDAQ
GOOGL
Alphabet
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유